Blood Borne Viruses Hepatitis C Overview Phlebotomists Association of Ireland Dr Ciaran Bannan Research Fellow St James’s Hospital / Trinity College Dublin.

Slides:



Advertisements
Similar presentations
Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV) Fuad AM Hasan Department Of Medicine Faculty of Medicine Kuwait University.
Advertisements

Hcv infection and management in advanced liver disease
The Hepatitis B&C Past and Present Martin J Spitz MD FACP AGAF Clinical Professor of Medicine UCSF.
Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California.
Hepatitis C and You  2014 Greenview Hepatitis C Fund All Rights Reserved.
Hepatitis B and Hepatitis B Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.
HCV: Treat now or Defer Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL JUNE 19,
Liver Disease and Thalassaemia George Constantinou.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.
Senate Health Care Committee Briefing: Hepatitis C Treatment Dan Lessler, MD Chief Medical Officer November 20, 2014.
Harvoni® ledipasvir/sofosbuvir
Global Hepatitis C Guidelines 2014: recommendations for a public health approach Gottfried Hirnschall.
Hep 202 Just when you thought you knew everything.
Hepatitis C Disease & Treatment.
Hepatitis C What’s New Alan Kilby, M.D. Portland Gastroenterology Center Maine Medical Center VTC Sept 27, 2013.
Management of HCV in Co-Infected Patients Marie-Louise Vachon, MD, MSc Division of Infectious Diseases Centre Hospitalier Universitaire de Québec.
Module 6: Treatment options. Module goal To enable participants understand the best current treatment options, factors that influence outcomes and potential.
Hepatitis C.
Hepatitis C for the General Practitioner Morris Sherman MB BCh PhD FRCP(C) University of Toronto January 2013.
HEPATITIS C CO-INFECTION
Greenview Hepatitis C Fund Deborah Green Home: Cell: /31/2008.
Module 3: HCV prevalence and course of HCV infection.
Managing Hepatitis C: An Unprecedented Correctional Healthcare Challenge ASCA/CCHA meeting Phoenix, AZ RADM Newton E. Kendig Assistant Director/Medical.
HEPATITIS 2014 BC. CHRONIC HEPATITIS B THE PROBLEM 350,000,000 PEOPLE HAVE IT IT IS TRANSMITTED MOTHER TO CHILD WHERE IT IS ENDEMIC IT CAN BE TRANSMITTED.
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
This is the most comprehensive compilation of epidemiological information on Hepatitis C Graciously provided by the University Hepatitis Center (last updated.
NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.
Prabhdeep Sidhu Candidate PharmD 2015 Western University of Health Sciences Mar 28, 2014.
Future Therapies of HCV Miranda Surjadi, NP San Francisco General Hospital Department of Gastroenterology/Hepatology.
Hepatitis C: The Next Tsunami Danny Jenkins Cri-Help Common Ground – The Westside HIV Community Center We Write the Grants
Patient Information - Viral Hepatitis B (HBV)
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 5 or 6 Robert G. Gish MD Staff Physician, Stanford University.
Maria Buti Hospital General Universitario Vall Hebron Barcelona-. Spain Relapser or Non Responder? Chronic Hepatitis C.
How to optimize treatment of G1 patients? Prof. G. K. K. Lau 2012.
Module 4: Testing and monitoring. Module 5: Testing and monitoring Module goal To introduce participants to best practice regarding the different tests,
Sources of Hepatitis C Infection (U.S.) Previously Acquired (
HEPATITIS C VIRUS Dr. Magdy Muharram. What is Hepatitis?  “Hepatitis” means inflammation of the liver  Can be caused by:  Genetic diseases  Medications.
FDA Hepatitis C Hearing Oct 19, 2006 Jules Levin Executive Director/Founder, NATAP National AIDS Treatment Advocacy Project.
BOCEPREVIR & TELAPREVIR
SAPPHIRE-I Feld JJ. NEJM 2014;370: SAPPHIRE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for genotype 1  Treatment regimens.
HEPATITIS C Kimberly Klatt. CHARACTERISTICS  Virus  Enveloped  Single-stranded RNA virus  High mutation rate  6 different genotypes  Most cases.
Hepatitis C: Perspective on Drug Development Issues Debra Birnkrant, M.D. Director, Division of Antiviral Products FDA Antiviral Drugs Advisory Committee.
Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.
Hepatitis C Past, present and future Salil Singh Consultant Gastroenterologist, RBH
Hepatitis C Infection By: S/N Maryam Omar. Introduction  Thalassemia patient require life long blood transfusion to sustain their growth and development.
Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.
Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4):
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C Edward J. Gane, M.D., Catherine A. Stedman, M.B., Ch.B. New Engl J Med 2013;
Daniel Dhumeaux, Henri Mondor hospital Créteil, France HCV compassionate use programme The French experience Amsterdam, April.
Viral hepatitis overview Itodo Ewaoche 27/02/2015.
Setting the Scene. Non A, non B Hepatitis  Early 1970’s recognised that 2/3 of post transfusional hepatitis were –ve for both Hep A & Hep B Non Hep A.
R2. 임형석 / Pf. 김병호. I NTRODUCTION Chronic hepatitis C infection 130~150 million worldwide 7 genotypes genotype 1 predominates(about 70% in USA): most difficult.
HBV. Overview of the Epidemiology of Hepatotropic Viruses.
Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):
Hepatitis B virus infection in renal transplant recipients
129 patients with chronic hepatitis C
The changing landscape of hepatitis infection
Effectiveness of Sofosbuvir in terms of sustained virological response at 12 weeks after treatment (SVR12) BETWEEN treatment naïve AND treatment.
HCV & liver transplantation
Sofosbuvir and Ledipasvir Combination with and without Ribavirin in Patients with Hepatitis C Virus Infection; Preliminary Report of an Experience from.
Diagnosis and Point of Care Testing of Hepatitis C
DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?
The ABCDE of Viral Hepatitis Phase 2a Liver Symposium
Talking to Patients About HCV Treatment
Treating Hep C with Novel Agents
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Just when you thought you knew everything.
A Real Life Study on Treatment of Egyptian Patients with HCV Genotype IV with Simeprevir and Sofosbuvir Prof.dr.Abdel fattah hanno Dr. Doaa al wazzan.
From non-A, non-B hepatitis to hepatitis C virus cure
بسم الله الرحمن الرحيم.
Presentation transcript:

Blood Borne Viruses Hepatitis C Overview Phlebotomists Association of Ireland Dr Ciaran Bannan Research Fellow St James’s Hospital / Trinity College Dublin 11 th April 2015

Aims of Talk Introduction to Hepatitis C Diagnosis Staging Treatment options –Old and New Future perspectives

Introduction Main causes of chronic liver disease Long term impact highly variable –Minimal changes –Chronic hepatitis –Extensive fibrosis –Cirrhosis –Hepatocellular carcinoma (HCC) Many people unaware of diagnosis

Hepatic Fibrosis Cirrhosis Liver Cancer Healthy Liver

Epidemiology 130 – 210 million affected –3% of world’s population Prevalence varies widely –Western Europe 0.3% - 3% –Higher in Eastern Europe and Middle East –Egypt – highest prevalence 9% Recent discovery – 1989/1990 –Approximately 10 years after HIV

Prevalence - WHO

Risk factors People who inject drugs (PWID) Blood transfusions / products Iatrogenic / Occupational Tattoos / Acupuncture Intranasal drug abuse e.g. cocaine Men who have sex with Men (MSM) Heterosexual and perinatal risk - v low Unknown

Most likely risk factor (%) for cases of hepatitis C notified (where data available, n=2354, 57%)

Genotypes Six genotypes described –Large number of subtypes Genotype 1 most prevalent worldwide –Subtype 1a – USA / Ireland –Subtype 1b – Europe Genotype 3 – Common in European IVDU Genotype 4 – Increasing incidence Genotype 5 and 6 rarely found

Natural history of HCV

Natural history Acute HCV asymptomatic in 70-80% of cases Chronic hepatitis develops in 75% of cases –Associated with variable degrees of hepatic inflammation and fibrosis progression –Independent of genotype and viral load

Accelerators of liver disease progression Alcohol Diabetes mellitus / Increased BMI Older age of acquisition HIV co-infection Hepatitis A/B/D co-infection –Vaccinate! Depending on presence of co-factors % of patients will develop cirrhosis

Hepatocellular Carcinoma Cirrhotic patients have 4% risk of death per year Hepatitis C has become the leading cause of primary liver cancers in Europe HCC occurs in cirrhotic patients at a rate of 1-5% per year Patients diagnosed with HCC have a 33% probability of death in the first year of diagnosis

Diagnosis Diagnosis is based on presence of both –Anti-HCV antibodies May not be positive until 6/12 after infection Detected by enzyme immunoassays New combined antigen-antibody test –HCV RNA Detected by molecular assays Appears before antibodies Genotyping should be requested

Assessment of disease severity Important in decision making in chronic Hepatitis C management and prognosis –Liver biopsy – gold standard –Requires at least day ward admission –Complications Bleeding Pain Pneumothorax Infection

Assessment of disease severity Non invasive methods –Fibroscan measures hepatic elastography (liver stiffness) Good for mild fibrosis and cirrhosis Not good for moderate and severe fibrosis

Assessment of disease severity Non invasive methods –Serological and blood markers –Coagulation – High INR –Low albumin –High Bilirublin –High LFTs –Low platelets –Low sodium

Diagnosis Summary HCV Antibody and PCR for RNA Genotype –Different treatment options and different responses to treatment Stage disease – invasive / non invasive

Treatment Goal of treatment is to eradicate infection Endpoint of treatment is a sustained virological response (SVR) –>99% chance of cure SVR is defined as no detectable virus 12 weeks after completion of treatment

Rationale for antiviral therapy Stop viral replication Normalisation of liver biochemistry Reduction in histologic activity Halt progression of disease Prevent Hepatocellular Carcinoma

Date of download: 9/23/2014 Copyright © 2014 American Medical Association. All rights reserved. From: Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis JAMA. 2012;308(24): doi: /jama

Treatment strategies Interferon alpha injections –Previously 3 times a week –Pegylated interferon Subcutaneous injection Weekly dosing Daily oral ribavirin tablets –Taken twice a day (usually 5-6 tablets daily)

Side Effects Common –Metabolic – loss of appetite –Psychiatric – Depression, poor sleep pattern –CNS – Headache, poor concentration –Respiratory – Cough, SOB –Gastrointestinal –Haematology – Low WCC, Hb, Plts –Skin and joint complaints –Endocrine – Thyroid disease

Contraindications Uncontrolled depression, psychosis, epilepsy or substance abuse Uncontrolled autoimmune disease Pregnant women Severe concurrent medical conditions Unwilling to comply with contraception Decompensated cirrhotic patients –Can consider Childs Pugh B in some circumstances

The Future … 2013 Directly Acting Antiviral (DAA) drugs Two drugs first to market: –NS3/NS4A Protease Inhibitors –Telaprevir –Boceprevir –Genotype 1 patients only –Given with interferon and ribavirin Multitude of new drugs in pipeline

Irish Results GUIDE Department in St James’s Hospital Included majority of patients with HIV –Pegylated interferon and Ribavirin –SVR rate of 58% for all genotypes –SVR rate of 37% for genotype 1 –Telaprevir / Boceprevir based therapy –SVR rate of 84% for genotype 1

Adapted from the US Food and Drug Administration, Antiviral Drugs Advisory Committee Meeting, April 27-28, 2011, Silver Spring, MD. SVR (%) IFN 6 mos PegIFN/ RBV 12 mos IFN 12 mos IFN/RBV 12 mos PegIFN 12 mos Standard IFN RBV PegIFN 1991 DAAs PegIFN/ RBV/ DAA IFN/RBV 6 mos DAA + RBV ± PegIFN The Good News

Treatment Limitations Treatment is more effective but much more difficult

Other Issues With PI-Based Therapy Pill burden Food requirement CYP3A4 PI metabolites Drug-drug interactions Resistance BOC = 12/day RBV = 4-7/day TVR = 6/day RBV = 4-7/day

New DAAs: Sites of action Ref: Feeney E.R, Chung R.T. Antiviral treatment of Hepatitis C. BMJ 2014;349:g3308..

Not All Direct-Acting Antivirals are Created Equal Characteristic Protease Inhibitor * Protease Inhibitor ** NS5A Inhibitor Nuc Polymerase Inhibitor Non-Nuc Polymerase Inhibitor Resistance profile Pangenotypic efficacy Antiviral potency Adverse events Good profileAverage profile Least favourable profile *First generation. **Second generation. Feld J. Keeping up in HCV: Counting down the final days of interferon. Clinical Care Options Hepatitis

Ideal Hepatitis C treatment 100% Efficacy Oral Interferon free Short duration No resistance Pan-genotypic Well tolerated Safe Low cost

New Drugs – Interferon free Gilead –Sofosbuvir (NS5B polymerase inhibitor) –Ledipasvir (NS5A Inhibitor) Abbott –Ombitasvir (NS5A inhibitor) –Paritaprevir/ritonavir (Protease inhibitor) –Dasabuvir (NS5B polymerase inhibitor) Ribavirin still needed in advanced cases

Who to treat? Treatment should be initiated promptly in those with advanced fibrosis and strongly considered in those with moderate fibrosis In individuals with less severe disease, indication for therapy is individual –Can wait for new therapies

Conclusion Very exciting time for Hepatitis C Need to identify cases and prioritise treatments to those who need it most Cost is a huge factor –Finding new cases –Financing treatment –Delivering treatment Managing drug-drug interactions

Prevention Very effective vaccines available for Hepatitis A and B Effective safe vaccine would help Ongoing Phase 1 and 2 studies with various vaccine candidates that show good promise to date

Questions - ?